Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease

BACKGROUND: Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD exacerbations. We hypothesized that short-acting β(2)-agonist (SABA) reliever use would...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, Christine R., Postma, Dirkje S., Anzueto, Antonio R., Make, Barry J., Peterson, Stefan, Eriksson, Göran, Calverley, Peter M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546184/
https://www.ncbi.nlm.nih.gov/pubmed/26293575
http://dx.doi.org/10.1186/s12890-015-0077-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546184/
https://www.ncbi.nlm.nih.gov/pubmed/26293575
http://dx.doi.org/10.1186/s12890-015-0077-0

Ejemplares similares